East Hanover, NJ, September 3, 2010 /24-7PressRelease/ -- Dr. James E. Foley, Diabetes Expert in the Global Clinical Research & Development Department at Novartis Pharmaceutical Corp. has been recognized by Cambridge Who's Who for demonstrating dedication, leadership and excellence in his career.

Dr. Foley started his work in the diabetes field in the 1970's first as a graduate student and then a post doc at Dartmouth Medical School. He was then a Visiting Scientist at the University of Arhus in Denmark in 1979 and 1980. Dr. Foley was Sr. Fellow with the NIH Pima Indian Project between 1981 and 1986 where he was member of the core team that started the Pima Prospective Study. Between 1986 and 1997 he was the Director of the Diabetes Research Program at Sandoz that invented vildagliptin (Galvus/Eucreas/Equa) and had identified nateglinide (Starlix) as a licensing opportunity. In 1998 following the merger of Sandoz and Ciba into Novartis, he moved into the New Products Commercialization & Medical Affairs Departments to develop the global Phase IV Plan for Starlix. In 2001 following the launch of Starlix in the U.S., Dr. Foley moved to Global Clinical Research & Development where he took the lead in developing the vildagliptin clinical mechanism program. Dr. Foley is an author on over 135 publications. He has been a member of the ADA and EASD for more than 25 years and is reviewer for numerous journals publishing in areas of diabetes and metabolism. In his current position he is involved in designing, interpreting and publishing clinical studies as well as speaking to international audiences about vildagliptin.

About Cambridge Who's Who
With over 400,000 members representing every major industry, Cambridge Who's Who is a powerful networking resource that enables professionals to outshine their competition, in part through effective branding and marketing. Cambridge Who's Who employs similar public relations techniques to those utilized by Fortune 500 companies and makes them cost-effective for members who seek to take advantage of its career enhancement and business advancement services. Cambridge is pleased to welcome its new Executive Director of Global Branding and Networking, Donald Trump Jr., who is eager to share his extensive experience in this arena with members.

Cambridge Who's Who membership provides individuals with a valuable third party endorsement of their accomplishments and gives them the tools needed to brand themselves and their businesses effectively. In addition to publishing biographies in print and electronic form, it offers an online networking platform where members can establish new professional relationships.

Headquartered in Long Island's premier office building, RXR Plaza, the Cambridge Who's Who staff spans more than 10 departments and comprises a team of nearly 200 highly skilled and dedicated employees. Together they work to provide members with the recognition and exposure needed to further their careers, expand their businesses and network effectively in an economy where referrals are more important than ever.

For more information, please visit http://www.cambridgeregistry.com.

# # #